The NEC baby formula lawsuit landscape shifted dramatically this spring, and it is about to shift again. On April 9, 2026, a Cook County jury handed four families a combined $70 million verdict against Abbott Laboratories — the third major plaintiff victory in state court and the first multi-family Illinois trial in this litigation’s history. Now, with more than 800 lawsuits active in federal court and Abbott reaching agreements to resolve approximately 2,000 claims, the litigation is entering a pivotal new phase. The federal docket faces its own inflection point: Inman v. Mead Johnson, the first Enfamil case to survive federal summary judgment, was cleared to proceed to trial after Judge Pallmeyer rejected Mead Johnson’s attempt to have the lawsuit thrown out on May 8, 2026. With verdicts paid out to plaintiffs totaling more than $555 million, a Bloomberg Intelligence estimate placing total liability at $3 billion, and the Illinois Fifth District Appellate Court granting Mead Johnson a new trial in one key case, families and legal observers are watching every courtroom closely. Here is everything you need to understand about where this litigation stands — and where it is headed.
The April 9 Cook County Verdict: What the $70M Win Means
The Cook County verdict was a milestone on multiple fronts. Four families whose premature infants developed necrotizing enterocolitis (NEC) — a severe, life-threatening gastrointestinal disease that destroys intestinal tissue primarily in preterm babies — pursued their claims together in the first consolidated multi-family NEC trial in Illinois state court. The jury awarded $53 million in compensatory damages and an additional $17 million in punitive damages, totaling $70 million. All four infants survived, but three required surgery and all suffered severe, lasting complications after being fed Abbott’s Similac Special Care 24 in Chicago-area NICUs.
The punitive damages component is particularly significant. The court permitted punitive damages after finding evidence that Abbott may have concealed the NEC risks associated with Similac Special Care 24 from parents and NICU providers. That finding echoes the core allegation running through every NEC baby formula lawsuit filed across the country: that Abbott and Mead Johnson knew cow’s milk-based premature infant formula significantly elevated NEC risk compared to human breast milk fortifiers, yet failed to provide adequate warnings. If you are assessing the potential value of a defective product injury claim involving a NICU infant, a medical malpractice calculator can help you model the range of compensatory and punitive outcomes based on injury severity and jurisdiction.
Abbott maintains that the FDA has found no conclusive evidence linking its formula to NEC and points to independent research in its defense. The company has signaled it will appeal the Cook County verdict, consistent with its posture following earlier adverse state-court rulings.
The Federal Docket: Three Defense Wins, Then a Turning Point
Understanding why Inman v. Mead Johnson matters requires understanding what came before it. MDL 3026 — formally In re Abbott Laboratories et al., Preterm Infant Nutrition Products Liability Litigation — is consolidated in the Northern District of Illinois before Judge Rebecca Pallmeyer. As of July 1, 2026, the MDL contains more than 800 active cases, a number that has continued to grow even as the parties have begun resolving some claims. Abbott won the first three federal bellwether trials on summary judgment in 2025, with Judge Pallmeyer excluding plaintiffs’ causation experts under the rigorous Daubert standard in each instance. Those rulings left the federal docket looking deeply unfavorable for plaintiffs — until May 8, 2026, when Judge Pallmeyer ruled that Inman v. Mead Johnson can proceed to trial, rejecting Mead Johnson’s attempt to have the lawsuit thrown out. That ruling marked the first time a plaintiff’s causation theory survived federal scrutiny in this litigation, fundamentally changing the calculus for both sides.
The distinction between the federal MDL and state-court proceedings is critical for families evaluating their options. State courts have generally applied more permissive evidentiary standards, which helps explain why plaintiffs have achieved significant verdicts in Illinois and Missouri while the federal docket remained a graveyard for plaintiff claims through most of 2025. The Inman ruling signals that the federal landscape may finally be shifting. Mead Johnson, the maker of Enfamil, faces liability exposure in the federal MDL that could rival Abbott’s state-court exposure if plaintiff-friendly outcomes begin to replicate at the federal level.
For families whose cases are currently pending in MDL 3026, the procedural posture of their individual claim — including which causation experts have been designated and whether those experts’ methodologies survive Daubert — will likely determine whether their case advances toward trial or settlement. Consulting with litigation counsel familiar with the specific expert testimony that survived in Inman is essential for any family assessing next steps in the federal system.
State-Court Scoreboard: $555M+ in Verdicts and a New Trial Bombshell
While the federal MDL struggled through a string of defense wins in 2025, state courts have delivered a dramatically different picture. Verdicts paid out to plaintiffs across NEC baby formula lawsuits have now totaled more than $555 million, reflecting a string of plaintiff victories in Illinois and Missouri that have placed enormous settlement pressure on both Abbott and Mead Johnson.
The Missouri litigation produced the largest single verdict in this litigation’s history. A St. Louis jury awarded a family $495 million against Mead Johnson, a verdict that initially appeared to represent the high-water mark for plaintiff recoveries. That verdict was subsequently upheld on appeal, cementing its significance as a liability benchmark. However, the state-court scorecard is not without complexity for plaintiffs. On June 12, 2026, the Illinois Fifth District Appellate Court granted Mead Johnson a new trial, reversing a prior $60 million verdict. The appellate court based its ruling on trial misconduct, handing the defense a meaningful procedural victory even as the broader verdict landscape remains tilted toward plaintiffs. That reversal serves as a reminder that large jury verdicts are not always the final word — appellate review can undo years of plaintiff litigation work based on courtroom conduct issues that have nothing to do with the underlying merits.
Abbott’s state-court exposure has grown substantially across Illinois. In addition to the April 9, 2026 Cook County verdict, earlier Illinois juries returned significant verdicts against the company in 2024 and 2025. The cumulative weight of those verdicts — combined with the ongoing cost of litigation and the reputational pressure of repeated jury findings against the company — appears to be influencing Abbott’s approach to resolution. On August 20, 2026, Abbott reached agreements with three law firms to resolve approximately 2,000 claims relating to the company’s specialty formulas for preterm infants, representing the most significant movement toward global resolution in the litigation’s history.
For families tracking the litigation, the state-court verdicts serve two practical functions. First, they establish damages benchmarks that inform settlement valuations in individual cases. Second, they create public pressure on defendants that is difficult to quantify but impossible to ignore. When juries in multiple jurisdictions repeatedly find that formula manufacturers concealed known risks from parents of premature infants, the reputational and financial stakes of continued litigation rise with each verdict.
What Comes Next: Abbott’s Settlement Agreements and the Road Ahead
The August 20, 2026 settlement agreements between Abbott and three law firms — covering approximately 2,000 claims — represent the most consequential development in this litigation since the $495 million Missouri verdict. While the financial terms of those agreements have not been publicly disclosed, the sheer volume of claims being resolved suggests that Abbott has concluded that continued trial-by-trial attrition is more costly than negotiated resolution. That conclusion, if correct, would be consistent with how major mass tort litigations have historically moved toward global settlement: a critical mass of adverse verdicts eventually tips the calculus in favor of structured resolution.
Mead Johnson’s posture remains somewhat distinct. The June 12, 2026 appellate victory — which granted a new trial and reversed the $60 million verdict — gives Mead Johnson a procedural win it can point to as it resists settlement pressure. At the same time, the Inman v. Mead Johnson case proceeding toward trial in federal court means that Mead Johnson cannot simply wait out the litigation. If Inman produces a plaintiff verdict at the federal level, it would eliminate the last structural advantage defendants have maintained in this litigation: the argument that federal courts are inhospitable to NEC plaintiff claims.
For families who have not yet filed claims, the Abbott settlement agreements and the expanding federal docket carry important implications. Litigation of this complexity typically involves statutes of limitations that vary by state, and delay in consulting counsel can foreclose otherwise viable claims. The fact that Abbott has now moved toward resolution of thousands of claims does not mean that all remaining families will have straightforward paths to recovery — particularly in the federal MDL, where causation standards remain demanding and individual case circumstances matter enormously.
Legal observers expect the pace of resolution to accelerate through the remainder of 2026, particularly if the Inman trial produces another plaintiff verdict. A federal win for plaintiffs would likely trigger intensified settlement discussions across the MDL and could prompt Mead Johnson to pursue its own global resolution conversations similar to what Abbott began pursuing in August 2026. The Bloomberg Intelligence estimate of $3 billion in total liability across both defendants suggests that the litigation has meaningful runway remaining even after Abbott’s recent settlement agreements.
Frequently Asked Questions About the NEC Baby Formula Lawsuit
What is the NEC baby formula lawsuit, and who can file one?
The NEC baby formula lawsuit refers to the nationwide litigation brought by families of premature infants who developed necrotizing enterocolitis after being fed cow’s milk-based formula — primarily Abbott’s Similac Special Care and Mead Johnson’s Enfamil — in hospital NICUs. NEC is a devastating gastrointestinal disease that can cause permanent intestinal damage, require surgical removal of portions of the bowel, and result in death. Scientific research has found that premature infants fed cow’s milk-based formula face significantly elevated NEC risk compared to infants fed human breast milk or donor milk, and the central allegation in these lawsuits is that Abbott and Mead Johnson knew about this elevated risk but failed to adequately warn parents and medical providers.
Families who may be eligible to file a claim generally include those whose premature infant was fed Abbott or Mead Johnson cow’s milk-based formula in a NICU and subsequently developed NEC, experienced severe intestinal complications, underwent bowel surgery, or died. Claims can be filed by parents or legal guardians on behalf of surviving children, or by estates on behalf of infants who did not survive. Because statutes of limitations vary by state — and because some states have shorter deadlines for claims involving minors than adults might expect — families should consult with an attorney promptly rather than assuming they have unlimited time to act.
What did the April 9, 2026 Cook County verdict decide?
The April 9, 2026 Cook County verdict resolved claims brought by four families whose premature infants developed NEC after being fed Abbott’s Similac Special Care 24 in Chicago-area NICUs. The jury awarded $53 million in compensatory damages and $17 million in punitive damages, for a combined total of $70 million. All four infants survived, but each suffered severe and lasting complications, with three requiring surgical intervention.
The verdict is significant for several reasons beyond its dollar amount. It was the first consolidated multi-family NEC trial in Illinois — a format that allowed four families’ claims to be heard together, increasing efficiency and allowing the jury to evaluate a pattern of alleged corporate conduct rather than a single isolated incident. The inclusion of punitive damages, based on evidence that Abbott may have concealed known NEC risks, reflects a judicial finding that the case involved more than ordinary product liability. Abbott has indicated it intends to appeal, consistent with its response to prior adverse verdicts, but the Cook County outcome adds to a cumulative record of jury findings against the company that is increasingly difficult to dismiss as outliers.
Why is the Inman v. Mead Johnson case so important?
Inman v. Mead Johnson is the first Enfamil NEC case to survive federal summary judgment in MDL 3026. Judge Pallmeyer’s May 8, 2026 ruling — rejecting Mead Johnson’s motion to have the case thrown out — marked a decisive turning point in the federal litigation. Prior to that ruling, Abbott had won all three federal bellwether trials on summary judgment, with plaintiffs’ causation experts excluded under the Daubert standard in each instance. Those outcomes had created a perception that the federal docket was effectively closed to plaintiff recovery.
The Inman ruling changes that calculus entirely. For the first time, a federal jury will be asked to evaluate whether Mead Johnson’s Enfamil caused a premature infant’s NEC and whether the company failed to provide adequate warnings. If the jury returns a plaintiff verdict, it would validate the causation theories that have driven plaintiff success in state courts and potentially unlock a wave of federal settlements. If Mead Johnson prevails, it would reinforce the argument that federal courts remain hostile terrain for NEC plaintiffs and likely embolden the defense to resist broader resolution. Either way, the Inman outcome will shape the trajectory of the more than 800 cases currently pending in the federal MDL.
What is the current total of verdicts in the NEC baby formula lawsuit litigation, and what do they mean for settlement?
Verdicts paid out to plaintiffs in NEC baby formula lawsuits have totaled more than $555 million as of mid-2026. That figure reflects a series of significant plaintiff victories in Illinois and Missouri state courts, including the $495 million Missouri verdict against Mead Johnson and multiple Cook County verdicts against Abbott. The cumulative verdict total does not include the approximately 2,000 claims that Abbott agreed to resolve through settlement agreements reached on August 20, 2026, the terms of which have not been publicly disclosed.
For families with pending claims, the verdict total serves as a reference point for understanding the realistic range of potential outcomes — but it is important to recognize that individual case values vary substantially based on injury severity, the infant’s medical history, the jurisdiction where the claim is filed, and the specific formula and NICU circumstances involved. Verdicts in bellwether trials are also subject to appeal, as illustrated by the June 12, 2026 Illinois appellate court decision granting Mead Johnson a new trial and reversing the prior $60 million verdict on misconduct grounds. The Bloomberg Intelligence estimate of $3 billion in total potential liability across both defendants suggests that even after Abbott’s recent settlement agreements, the litigation has substantial unresolved exposure remaining.
How long do NEC baby formula lawsuits take, and is there a settlement yet?
NEC baby formula lawsuits vary significantly in duration depending on whether a case is filed in state or federal court, where in the litigation queue it sits, and how the defendants choose to respond. Cases in state court that proceeded to trial in 2024 and 2025 took several years from filing to verdict. Federal MDL cases face additional complexity because they must navigate centralized pretrial proceedings, expert discovery, and the Daubert gatekeeping process before advancing toward trial.
As of August 2026, there is no global settlement that resolves all claims. Abbott reached agreements with three law firms on August 20, 2026, to resolve approximately 2,000 claims, representing the most significant resolution effort to date — but those agreements cover a specific subset of cases and their terms have not been made public. Mead Johnson has not announced comparable resolution efforts, though the Inman trial’s outcome is expected to significantly influence whether and when Mead Johnson pursues broader settlement discussions. Families who have filed claims should maintain regular communication with their attorneys about case status, and families who have not yet filed should consult with counsel promptly to ensure they do not miss applicable statutes of limitations deadlines.
Victoria Chambers is a mass tort and class action research analyst with extensive knowledge of multi-district litigation (MDL), defective product cases, dangerous drug lawsuits, and toxic exposure claims across the United States. Victoria is not an attorney and the information provided is for educational purposes only.